Early Safety And Efficacy Results With A Single Dose Of Autologous Crispr-Cas9-Modified Cd34+Hematopoietic Stem And Progenitor Cells In Transfusion-Dependent Beta-Thalassemia And Sickle Cell Disease

BRITISH JOURNAL OF HAEMATOLOGY(2021)

引用 0|浏览8
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要